The Akt1 isoform is an essential mediator of ischaemic preconditioning

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 8, 2012, Pages 1739-1749

  Kunuthur, Suma P ^a   Mocanu, Mihaela M ^a   Hemmings, Brian A ^b   Hausenloy, Derek J ^a   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Akt isoforms; in vivo myocardial ischaemia reperfusion injury; Ischaemic preconditioning

Indexed keywords

AKT1 PROTEIN, MOUSE; AKT2 PROTEIN, MOUSE; ISOENZYME; PROTEIN KINASE B;

AGING; ANIMAL; ARTICLE; C57BL MOUSE; ENZYMOLOGY; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE; HEMODYNAMICS; HYPERGLYCEMIA; IMMUNOBLOTTING; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SURVIVAL;

AGING; ANIMALS; HEMODYNAMICS; HYPERGLYCEMIA; IMMUNOBLOTTING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; ISOENZYMES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

MUS;

EID: 84864378837     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01491.x     Document Type: Article

References (57)

1. Chae HJ, Kim HR, Bae J, et al. Signal transduction of the protective effect of insulin like growth factor-1 on adriamycin-induced apoptosis in cardiac muscle cells. Arch Pharm Res. 2004; 27: 324-33.
2. Hong F, Kwon SJ, Jhun BS, et al. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci. 2001; 68: 1095-105.
3. Brozinick JTJr, Birnbaum MJ. Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle. J Biol Chem. 1998; 273: 14679-82.
4. Matsui T, Li L, del M, et al. Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999; 100: 2373-9.
5. Cao CM, Zhang Y, Weisleder N, et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010; 121: 2565-74.
6. Wang B, Shravah J, Luo H, et al. Propofol protects against hydrogen peroxide-induced injury in cardiac H9c2 cells via Akt activation and Bcl-2 up-regulation. Biochem Biophys Res Commun. 2009; 389: 105-11.
7. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998; 335: 1-13.
8. Murthy SS, Tosolini A, Taguchi T, et al. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet. 2000; 88: 38-40.
9. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001; 26: 657-64.
10. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001; 15: 2203-8.
11. Cho H, Thorvaldsen JL, Chu Q, et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001; 276: 38349-52.
12. Yang ZZ, Tschopp O, Hemmings-Mieszczak M, et al. Protein kinase B alpha/Akt1 regulates placental development and foetal growth. J Biol Chem. 2003; 278: 32124-31.
13. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001; 292: 1728-31.
14. Garofalo RS, Orena SJ, Rafidi K, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest. 2003; 112: 197-208.
15. Easton RM, Cho H, Roovers K, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol. 2005; 25: 1869-78.
16. Tschopp O, Yang ZZ, Brodbeck D, et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005; 132: 2943-54.
17. Yang ZZ, Tschopp O, Di Poi N, et al. Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol. 2005; 25: 10407-18.
18. Dummler B, Tschopp O, Hynx D, et al. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol. 2006; 26: 8042-51.
19. Masure S, Haefner B, Wesselink JJ, et al. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur J Biochem. 1999; 265: 353-60.
20. DeBosch B, Treskov I, Lupu TS, et al. Akt1 is required for physiological cardiac growth. Circulation. 2006; 113: 2097-104.
21. DeBosch B, Sambandam N, Weinheimer C, et al. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem. 2006; 281: 32841-51.
22. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res. 2004; 61: 448-60.
23. Hausenloy DJ, Tsang A, Mocanu MM, et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005; 288: H971-6.
24. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995; 376: 599-602.
25. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem. 1998; 273: 19929-32.
26. Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004; 113: 1535-49.
27. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91: 231-41.
28. Fisher SG, Marber MS. An in vivo model of ischaemia-reperfusion injury and ischaemic preconditioning in the mouse heart. J Pharmacol Toxicol Methods. 2002; 48: 161-9.
29. Lim SY, Davidson SM, Hausenloy DJ, et al. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res. 2007; 75: 530-5.
30. Tong H, Chen W, Steenbergen C, et al. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res. 2000; 87: 309-15.
31. Tong H, Imahashi K, Steenbergen C, et al. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase- dependent pathway is cardioprotective. Circ Res. 2002; 90: 377-9.
32. Tsang A, Hausenloy DJ, Mocanu MM, et al. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005; 54: 2360-4.
33. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res. 2004; 63: 305-12.
34. Matsui T, Tao J, del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001; 104: 330-5.
35. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002; 277: 22896-901.
36. Cao Z, Liu L, Packwood W, et al. Sex differences in the mechanism of Met5-enkephalin-induced cardioprotection: role of PI3K/Akt. Am J Physiol Heart Circ Physiol. 2008; 294: H302-10.
37. Dreixler JC, Hemmert JW, Shenoy SK, et al. The role of Akt/protein kinase B subtypes in retinal ischemic preconditioning. Exp Eye Res. 2009; 88: 512-21.
38. Gomez L, Paillard M, Thibault H, et al. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation. 2008; 117: 2761-8.
39. Nishihara M, Miura T, Miki T, et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol. 2007; 43: 564-70.
40. Nishihara M, Miura T, Miki T, et al. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol. 2006; 291: H748-55.
41. Maulik N, Yoshida T, Zu YL, et al. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol. 1998; 275: H1857-64.
42. Stumpner J, Redel A, Kellermann A, et al. Differential role of Pim-1 kinase in anesthetic-induced and ischemic preconditioning against myocardial infarction. Anesthesiology. 2009; 111: 1257-64.
43. Miyawaki T, Mashiko T, Ofengeim D, et al. Ischemic preconditioning blocks BAD translocation, Bcl-xL cleavage, and large channel activity in mitochondria of postischemic hippocampal neurons. Proc Natl Acad Sci USA. 2008; 105: 4892-7.
44. Uchiyama T, Engelman RM, Maulik N, et al. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation. 2004; 109: 3042-9.
45. Lecour S, Suleman N, Deuchar GA, et al. Pharmacological preconditioning with tumour necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation. 2005; 112: 3911-8.
46. Mocanu MM, Bell RM, Yellon DM. PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol. 2002; 34: 661-8.
47. Fryer RM, Pratt PF, Hsu AK, et al. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J Pharmacol Exp Ther. 2001; 296: 642-9.
48. Solenkova NV, Solodushko V, Cohen MV, et al. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol. 2006; 290: H441-9.
49. Zhang J, Bian HJ, Li XX, et al. ERK-MAPK signaling opposes rho-kinase to reduce cardiomyocyte apoptosis in heart ischemic preconditioning. Mol Med. 2010; 16: 307-15.
50. Chen WS, Peng XD, Wang Y, et al. Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. Mol Cell Biol. 2009; 29: 3151-62.
51. Tosaki A, Engelman DT, Engelman RM, et al. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res. 1996; 31: 526-36.
52. Sivaraman V, Hausenloy DJ, Wynne AM, et al. Preconditioning the diabetic human myocardium. J Cell Mol Med. 2010; 14: 1740-6.
53. Mersmann J, Tran N, Zacharowski PA, et al. Rosiglitazone is cardioprotective in a murine model of myocardial I/R. Shock. 2008; 30: 64-8.
54. Nishida H, Sato T, Nomura M, et al. Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit hearts. J Pharmacol Sci. 2009; 109: 251-6.
55. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol. 2008; 103: 274-84.
56. Fields AV, Patterson B, Karnik AA, et al. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol. 2009; 32: 236-43.
57. Smith CC, Mocanu MM, Davidson SM, et al. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol. 2006; 149: 5-13.